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The human XPF-ERCC1 protein complex is one of sev-
eral factors known to be required for general nucleotide
excision repair. Genetic data indicate that both proteins
of this complex are necessary for the repair of inter-
strand cross-links, perhaps via recombination. To deter-
mine whether XPF-ERCC1 completes a set of six pro-
teins that are sufficient to carry out excision repair, the
human XPF and ERCC1 cDNAs were coexpressed in Sf21
insect cells from a baculovirus vector. The purified com-
plex contained the anticipated 5* junction-specific endo-
nuclease activity that is stimulated through a direct
interaction between XPF and replication protein A
(RPA). The recombinant complex also complemented ex-
tracts of XP-F cells and Chinese hamster ovary mutants
assigned to complementation groups 1, 4, and 11. Fur-
thermore, reconstitution of the human excision nucle-
ase was observed with a mixture of five repair factors
(XPA, XPC, XPG, TFIIH, and RPA) and the recombinant
XPF-ERCC1, thus verifying that no additional protein
factors are needed for the specific dual incisions char-
acteristic of human excision repair.
Nucleotide excision repair in humans consists of dual inci-
sions on both sides of the lesion in the damaged strand, which
results in excision of 24–32-nucleotide-long oligomers followed
by repair synthesis and ligation (1–3). The enzyme system
responsible for the dual incisions is referred to as excision
nuclease (2). Individuals lacking excision nuclease suffer from
xeroderma pigmentosum (XP),1 a disease that is character-
ized by photodermatoses and in some cases by neurological
abnormalities (4, 5).
Recently, human excision nuclease has been reconstituted
from highly purified proteins including those encoded by XPA
through XPG (6–8). These reconstitutions have helped define
the minimum essential set of proteins for the dual incision/
excision activity. It was found that all proteins encoded by the
XP genes with the exception of the XPE gene product were
required for excision. Other proteins necessary for this reaction
pathway are replication protein A (RPA, consisting of three
subunits), transcription factor TFIIH (composed of 5–8 sub-
units including XPB and XPD), and ERCC1 (which together
with XPF forms a distinct complex). These studies were con-
ducted with proteins purified mostly from human cells; there-
fore, a requirement for additional proteins that were present in
the reconstitution fractions as “contaminants” was a realistic
possibility. The need for additional unknown proteins was ar-
gued using evidence that a factor (IF7) of one or more proteins
that purified through several columns with XPF-ERCC1 and
finally separated from this complex by a DEAE resin was
essential for incision specificity by the reconstituted human
excision nuclease (8). However, a later report with proteins
purified to apparent homogeneity failed to confirm the need for
an additional factor (7). To clarify the discrepancy raised by
these studies, we attempted to use proteins expressed and
purified from heterologous systems because the presence of
trace amounts of IF7 cannot be excluded with the most exten-
sively purified human cellular preparations of XPF-ERCC1.
The recent cloning of XPF (ERCC4) (9) and subsequent isola-
tion of its cDNA (10, 11) provide the opportunity to produce the
recombinant XPF-ERCC1 complex in a surrogate host. Toward
this goal, we expressed the XPF-ERCC1 complex in abundance
using a baculovirus vector, purified the complex to homogene-
ity, and verified its activity as a junction-specific endonuclease
(12) that incises in the 59 direction of a DNA lesion (7). Recom-
binant XPF-ERCC1, referred to hereafter as r(XPF-ERCC1),
also complemented extracts of XP-F cells and hamster mutants
in complementation groups 1, 4, and 11. The complex is fully
capable of reconstituting human excision nuclease when com-
bined with TFIIH, XPC, and recombinant XPA, RPA, and XPG
proteins. Our data show that only these six factors are needed
for damage-specific dual incision by human excision nuclease.
MATERIALS AND METHODS
Antibodies—The NcoI-BamHI fragment of the XPF cDNA encoding
the N-terminal 260 amino acids of XPF was expressed from pET26b
(Novagen) in Escherichia coli BL21(DE3) and purified as described
previously (10). This polypeptide antigen was used to produce mouse
polyclonal antibodies. From one of the positive mice, a monoclonal cell
line (6D12) was identified and subcloned by standard procedures at the
University of California Berkeley Hybridoma Facility.
Plasmid Constructs—For the overexpression of the recombinant
XPF-ERCC1 complex in insect cells, both cDNAs were inserted into the
p2Bac vector (Invitrogen). First, the SacI-HindIII fragment of the pMal-
ERCC1 construct (13) containing the ERCC1 open reading frame (ORF)
was placed behind the PH promoter of p2Bac, resulting in the plasmid
p2Bac-E1. The ApaI-XbaI fragment of pcER4–34 containing the human
XPF ORF (10) was then inserted into p2Bac-E1, placing XPF under the
control of the P10 promoter and creating the final expression construct
p2Bac-FE1. Recombinant baculovirus was obtained by standard meth-
ods (14) using the BaculoGold transfection kit (PharMingen).
For in vitro transcription-translation, the ERCC1 and XPF ORFs
were inserted into the pIBI24 vector (IBI). In order to create the appro-
priate restriction sites for subcloning of XPF, 974 bp encoding the
N-terminal one-third of the ORF was amplified from the 59-end of
pcER4–34 using the following polymerase chain reaction primers: 59-
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CGCGAATTCAAGGATATAGCTCTAGAGATGGAGTCAGGCAGCCG-
GCTCGACGGATT and 59-AAACAGCCAACCTGAATTCTGACCAAA-
CGCTTTTTCCGTT. The XbaI-BamHI fragment of this polymerase
chain reaction product and the BamHI-ApaI fragment excised from
pcER4–34 carrying the 39 section of the XPF ORF were cloned into
pIBI24, placing XPF under the control of the T7 promoter and creating
pTB-F. The ERCC1 cDNA was similarly placed behind the T7 promoter
by inserting the SalI-XbaI fragment of pMal-ERCC1 into pIBI24,
creating pTB-E1.
Purification of Recombinant XPF-ERCC1—Sf21 cells (5 3 108) were
infected with the baculovirus expression construct p2Bac-FE1 at a
multiplicity of infection of 20, and cells were harvested 48 h after
infection. Cell-free extract was prepared as described previously (15)
and loaded onto a 20-ml SP-Sepharose column, and the column was
developed with a 200-ml linear gradient from 0.1 to 1.0 M KCl in Buffer
A (25 mM Hepes-KOH, pH 7.9, 12 mM MgCl2, 0.5 mM EDTA, 2 mM
dithiothreitol, and 15% glycerol). The r(XPF-ERCC1) complex that
eluted at about 0.4 M KCl was located with polyclonal anti-XPF anti-
bodies (10) and polyclonal anti-ERCC1 antibodies (16). Fractions con-
taining r(XPF-ERCC1) were combined, dialyzed against Buffer A 1 100
mM KCl, and then loaded onto a 5-ml glutathione S-transferase-XPA
affinity column (17). The affinity column was washed with 200 ml of
Buffer B (25 mM Hepes-KOH, pH 7.4, 100 mM KCl, 1 mM EDTA, 10 mM
b-mercaptoethanol, and 10% glycerol). r(XPF-ERCC1) complex was
eluted with 1.0 M KCl in Buffer B as indicated by both silver staining
and immunoblotting of SDS-polyacrylamide gels. Fractions containing
r(XPF-ERCC1) were collected and dialyzed against Buffer A plus 100
mM KCl. The yield was typically 150 mg of protein of high purity from 20
mg of total CFE.
Nuclease Assay—A 39-end-labeled 90-bp duplex and a 90-bp DNA
fragment with a 30-nucleotide unpaired sequence (“bubble”) in the
middle as described previously (12) were used as substrates to test for
nonspecific nuclease and junction-specific nuclease activities of r(XPF-
ERCC1), respectively. The reaction mixture (7.5 ml) contained 5 fmol of
DNA and the indicated amount of r(XPF-ERCC1) in nuclease buffer (25
mM Hepes-KOH, pH 7.9, 10 mM KCl, 3 mM MgCl2, 1 mM dithiothreitol,
100 mg/ml bovine serum albumin, and 6.5% (v/v) glycerol). The reaction
mixture was incubated at 37 °C for 30 min, and the products were
analyzed on 8% denaturing polyacrylamide gels followed by
autoradiography.
Complementation Assay with Mutant Cell-free Extracts—Reaction
mixtures contained 50 mg of mutant CFE, 20 ng of r(XPF-ERCC1), and
25 fmol of the 140-bp cholesterol A substrate (7) in 25 ml of excision
buffer (6, 7). The reaction was carried out at 30 °C for 60 min. For
cross-complementation, 25 mg of each mutant CFE was mixed in 25 ml
of excision buffer with substrate, and the reaction was carried out in an
identical manner. Excised fragments were analyzed on 8% denaturing
polyacrylamide gels. The mutant CFEs used in this study were XP-A
(GM02345B), XP-F (GM08437), ERCC-1 (UV20), ERCC-3 (UV24),
ERCC-4 (UV41), ERCC-5 (UV135), and ERCC-11 (UVS1).
In Vitro Transcription-Translation—[35S]Methionine-labeled XPF
and ERCC1 proteins were prepared by the TNT Coupled Reticulocyte
Lysate System (Promega) using pTB-F and pTB-E1 as templates, either
added separately or together in the reaction mixture following the
manufacturer’s instructions. 10 fmol of ERCC1, 4 fmol of XPF, and 4
fmol of XPF-ERCC1 were used for protein-protein interaction study.
DNA Binding Assay—A 90-bp duplex was terminally labeled with
[g-32P]ATP and T4 polynucleotide kinase as described (12). To obtain
UV-damaged DNA, the 90-bp duplex was irradiated with 2500 J/m2 of
254 nm light from a germicidal lamp at a fluence rate of 250 milliwatts/
cm2. For binding assays, 3 fmol of DNA was incubated with r(XPF-
ERCC1) in Buffer A containing 100 mM KCl for 10 min on ice. The
reaction mixtures were directly analyzed on 5% native polyacrylamide
gels run in 1 3 TBE buffer for 90 min at room temperature. The E. coli
UvrA protein that binds specifically to UV-irradiated DNA (18) was
FIG. 1. Purification of r(XPF-ERCC1). The r(XPF-ERCC1) com-
plex purified by SP-Sepharose and glutathione S-transferase-XPA af-
finity columns was analyzed on 8.5% SDS-polyacrylamide gel electro-
phoresis gels followed by silver staining or Western blotting using
anti-ERCC1 serum and anti-XPF polyclonal ascites. Lane 1, silver-
stained gel of purified protein (400 ng); lane 2, immunoblot of HeLa
CFE (100 mg); lane 3, immunoblot of recombinant protein (200 ng).
Positions of protein molecular mass standards in kDa are shown.
FIG. 2. Junction-cutting activity of
r(XPF-ERCC1). A, bubble-30 and dou-
ble-stranded DNA substrates. The 39-end-
labeled substrate was incubated with 20
ng (1) or 40 ng (11) of r(XPF-ERCC1) in
the absence (2) or presence (1) of RPA
(50 ng) as indicated. The 59 border of the
bubble is 57 nucleotides from the label,
and the major incision site is 61 nucleo-
tides from the label or 4 nucleotides 59 to
the single-stranded bubble region (12).
Double-stranded DNA substrate was in-
cubated with r(XPF-ERCC1) alone (20 ng,
lane 7) or r(XPF-ERCC1) (20 ng) and RPA
(50 ng, lane 8) as indicated. In lanes 2, 3,
4, and 5, 0.5, 28, 1.3, and 49% of the
substate were incised by r(XPF-ERCC1),
respectively. B, inhibition of r(XPF-
ERCC1) junction cutting by the anti-XPF
monoclonal antibody. The bubble sub-
strate was incubated with r(XPF-ERCC1)
(10 ng) alone (lane 2) or with r(XPF-
ERCC1) (10 ng) that had been preincu-
bated for 10 min on ice with 100 ng of
either anti-XPF monoclonal antibody
(lane 2) or an unrelated monoclonal anti-
body against proliferating cell nuclear an-
tigen (lane 3). Then, RPA (50 ng) was
added and incubation was continued at
37 °C for 30 min. In lane 2, 93% of the
junction-cutting activity of r(XPF-
ERCC1) was inhibited by anti-XPF anti-
body. Lane 4 contained DNA only.
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used as a positive control. Binding was quantified using a PhosphorIm-
ager (Molecular Dynamics, Sunnyvale, CA).
RESULTS AND DISCUSSION
Purification of Recombinant XPF-ERCC1—To obtain a
highly purified sample of XPF-ERCC1, we constructed a bacu-
lovirus expression vector (p2Bac-FE1) containing the cDNAs
from both ERCC1 and the recently cloned XPF (from pcER4–
34; Ref. 10). Infection of Sf21 insect cells resulted in overex-
pression of both proteins, which purified as a complex through
SP-Sepharose followed by XPA-affinity columns (16, 17). The
use of the XPA-affinity step enabled us to isolate 150 mg of
r(XPF-ERCC1) from 20 mg of cellular protein with greater than
95% homogeneity. This compares favorably with the yield of
,1.0 mg of protein purified from 22 g of HeLa CFE (from a
250-liter cell culture; Ref. 17). After separating the proteins by
SDS-gel electrophoresis, analysis by silver staining verified
that the preparation was free of protein contaminants (Fig. 1).
Antibodies to each of the two subunits detected proteins from
the purified preparation that migrated exactly as the 38-kDa
(ERCC1) and 112-kDa (XPF) proteins extracted from HeLa
cells. This agreement indicates that neither one of the overex-
pressed proteins undergoes post-translational modification in
Sf21 cells, and that the insect cells are capable of carrying out
the same post-translational modification as human cells.
Functional Properties of r(XPF-ERCC1)—Two related enzy-
matic activities have been attributed to XPF-ERCC1 that help
to explain its function in excision repair. The complex incises
the 59 junction of DNA bubble and loop structures four nucle-
otides 59 to the junction (12) and makes the 59 incision of the
dual incision human excision nuclease (7, 19). Purified r(XPF-
ERCC1) was tested for these properties. When a DNA bubble
substrate was used, r(XPF-ERCC1) made the specific cleavage
expected, and this activity was stimulated 40–50-fold by the
addition of RPA (Fig. 2A). The complex did not nick double-
stranded DNA (Fig. 2A, lanes 7 and 8). Incision activity was
severely inhibited by the anti-XPF monoclonal antibody, dem-
onstrating the dependence of the reaction on the XPF protein
(Fig. 2B).
We also tested r(XPF-ERCC1) for complementation of exci-
sion nuclease (20), an activity that we consider to be the most
specific for the native complex (17). r(XPF-ERCC1) was found
to complement extracts from XP-F cells and the Chinese ham-
ster ovary mutants of complementation groups 4 (ERCC4/
XPF) and 1 (ERCC1), but not extracts from XP-A cells and
groups 3 (ERCC3/XPB) and 5 (ERCC5/XPG) (Fig. 3). The
recombinant protein also complemented the Chinese hamster
ovary complementation group 11 mutant (21), which is now
known to be a member of group 4 (10, 11).
Protein and DNA Interactions of XPF and ERCC1—As we
have observed previously, XPF-ERCC1 complex binds tightly
to XPA, e.g. during its purification on the XPA-affinity column.
Moreover, XPF-ERCC1 appears to interact with the RPA pro-
tein, since the junction endonuclease activity is greatly stimu-
lated by RPA (12). To study the contribution of the two mem-
bers of the complex in these binding interactions, the proteins
were expressed either singly or in combination in an in vitro
transcription-translation system and tested for binding to XPA
or RPA (Fig. 4). In agreement with earlier reports (16, 22, 23),
we found that ERCC1 (lane 1) and XPF-ERCC1 (lane 3) bound
to XPA. XPF by itself weakly adsorbed to the XPA-affinity resin
(lane 2), suggesting that the association of the complex with
XPA is mediated mostly by ERCC1. In contrast, ERCC1 did not
bind to RPA (lane 5), as XPF did (lane 6), and therefore XPF
must mediate the binding of the complex to RPA (lane 7). These
results demonstrate that the binding observed previously (in
which XPF-ERCC1 bound to RPA with particularly high affin-
ity in the presence of the DNA bubble substrate (12)), occurs
through a direct interaction between XPF and RPA.
Although XPA (24), RPA (25, 26), and XPC (27) have been
FIG. 3. Complementation of mutant
cell-free extracts. The 140-bp duplex
DNA containing a single adducted choles-
terol A (7) was incubated with the indi-
cated mutant CFE to which either r(XPF-
ERCC1) (20 ng) was added (R), or, for
cross-complementation, CFE from Chi-
nese hamster ovary mutant group 3
(ERCC-3) was added as indicated (C). The
size of the major excision product (28 nu-
cleotides) is indicated by an arrow.
FIG. 4. XPF protein binds to XPA and RPA. 35S-Labeled proteins
were made by an in vitro transcription-translation system, and prod-
ucts were separated by SDS-gel electrophoresis (Input, 70% ERCC1,
40% XPF, and 20% XPF-ERCC1 used for the assay were loaded direct-
ly). Note that the expression of XPF results in a 70-kDa protein in
addition to the full-length product. This is a proteolytic fragment of XPF
that is also seen in aged HeLa CFE or after XPF expression in E. coli,
but not after XPF expression in insect cells. For binding to XPA the
transcription-translation product was mixed with maltose-binding pro-
tein-XPA attached to amylose beads and incubated at 4 °C for 1 h. After
extensive washing with Buffer A 1 0.5% Nonidet P-40, the resin was
placed in SDS-loading buffer, heated at 95 °C for 5 min, and analyzed
on an 8.5% SDS-gel. The input proteins were as follows: lane 1, ERCC1;
lane 2, XPF; lane 3, XPF-ERCC1; lane 4, UvrB-maltose-binding protein
bound to amylose and mixed with XPF-ERCC1 as a negative control. In
lanes 1, 2, and 3, 36%, 8%, and 7% of the input proteins were pulled
down, respectively. For binding to RPA, the radiolabeled proteins were
mixed with recombinant RPA (31), then anti-p34 monoclonal antibody
(Oncogene Science) and protein A-agarose were added, and the mixture
was incubated at 4 °C for 1 h. Bound proteins were analyzed as de-
scribed above. The lanes contained the following: lane 5, ERCC1; lane 6,
XPF; lane 7, XPF-ERCC1. The sample run in lane 8 was identical to
that in lane 7, but did not include the anti-p34 antibody. In lanes 6 and
7, 7% and 5% of the input proteins were co-immunoprecipitated,
respectively.
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found to bind somewhat specifically to damaged DNA, the issue
of damage recognition remains one of the unsolved questions of
the human excision nuclease reaction mechanism. We tested
for binding of r(XPF-ERCC1) to UV-damaged DNA to find out
if it contributed to damage recognition. However, unlike the
UvrA subunit of E. coli excision nuclease that discriminates
between damaged and undamaged DNA, r(XPF-ERCC1) bound
nearly as well to both substrates (Fig. 5). Thus, we conclude
that even though XPF-ERCC1 has an intrinsic affinity to DNA,
it does not contribute to locating lesions and in this respect is
comparable to the homologous Rad1-Rad10 protein complex of
Saccharomyces cerevisiae (28).
Reconstitution of Human Excision Nuclease with Purified
Proteins and r(XPF-ERCC1)—Although significant progress
has been made recently in identifying and assigning functions
to all of the proteins involved in human excision repair (6–8)
and the highly homologous S. cerevisiae system (29, 30), the
two reports on human excision nuclease differed on an impor-
tant point. Mu et al. (6, 7) found that XPA, RPA, TFIIH, XPC,
XPG, and XPF-ERCC1 were necessary and sufficient for recon-
stituting human excision nuclease, whereas Aboussekhra et al.
(8) reported that, in addition to these six proteins, an incision
factor (IF7) was required. In the latter report, this factor ap-
peared to be tightly bound to XPF-ERCC1 and was separated
from it at the last step of a 7-column purification scheme.
Therefore, the possibility remained that the nominally pure
XPF-ERCC1 complex used in other studies might contain IF7,
which would explain the discrepancy between the two reports.
Hence, we reasoned that r(XPF-ERCC1) purified from a heter-
ologous source would be useful for solving this problem. We
combined r(XPF-ERCC1) with the other known factors: XPA,
RPA, and XPG, overexpressed and purified from E. coli or
insect cells, and XPC and TFIIH, purified to near-homogeneity
from HeLa cells (7). This set of highly purified proteins was
able to carry out precise excision of an adducted oligonucleo-
tide, thus giving firm evidence that XPF-ERCC1 protein is both
necessary and sufficient to reconstitute human excision nucle-
ase when added to the other five excision repair factors (Fig. 6).
Indeed, studies with the highly homologous S. cerevisiae sys-
tem have arrived at the same conclusion; that is, the yeast
homologs of the six factors are necessary and sufficient for
specific incision/excision of UV-damaged DNA (29, 30).
CONCLUSION
Human excision nuclease has been reconstituted from puri-
fied repair factors and characterized in considerable detail (2,
3). However, the repair factors are of low cellular abundance,
precluding detailed mechanistic studies with proteins purified
from natural sources. Of the six repair factors, XPA, RPA, XPG,
and XPC are currently available in recombinant forms that can
be purified in abundant quantities. As reported here, the avail-
ability of the XPF cDNA (10) has enabled us to demonstrate
direct interaction of XPF with RPA, a finding that may help
explain how RPA stimulates the nuclease function of XPF-
ERCC1 and how it may target it to its proper site of action in
the excision nuclease complex. The use of recombinant protein
in the reconstituted system has also confirmed that no addi-
tional factors are needed for reconstituting human excision
nuclease. When the recombinant form of TFIIH becomes avail-
able, it will be possible to perform mechanistic experiments
with human excision nuclease such as those that have been
conducted with prokaryotic excision nuclease for many years.
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